SCHEMBL6292579

SCHEMBL6292579

CCCC1=C(C(=O)OCC)C(c2cccc(Cl)c2C)c2c[nH]nc2N1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.44
TBXA2R P21731 3/20 0.44
ADRA1A P35348 3/20 0.44
SLC6A3 Q01959 3/20 0.44
ABCB11 O95342 3/20 0.44
LMNA P02545 3/20 0.44
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 2/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C19 P33261 2/20 0.44
KMT2A Q03164 2/20 0.44
HIF1A Q16665 2/20 0.44
HSD17B10 Q99714 2/20 0.44
TSHR P16473 2/20 0.44
ABCB1 P08183 2/20 0.44
ADORA3 P0DMS8 2/20 0.44
ADRB3 P13945 2/20 0.44
OPRK1 P41145 2/20 0.44
SCN5A Q14524 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6293510 0.92 CYP2C9 (0.54) CYP2C9TBXA2RADRA1ASLC6A3ABCB11
SCHEMBL6292289 0.92 TBXA2R (0.48) CYP2C9TBXA2RADRA1ASLC6A3ABCB11
SCHEMBL6292296 0.90 CYP2C9 (0.43) CYP2C9TBXA2RADRA1ASLC6A3ABCB11
SCHEMBL6292574 0.88 NR3C2 (0.41) CYP2C9TBXA2RADRA1ASLC6A3ABCB11
SCHEMBL6293728 0.88 CYP2C9 (0.44) CYP2C9TBXA2RADRA1ASLC6A3ABCB11
SCHEMBL6293386 0.86 TBXA2R (0.46) CYP2C9TBXA2RADRA1ASLC6A3ABCB11
SCHEMBL6296991 0.85 NR3C2 (0.45) LMNAKDM4EMEN1KMT2AHSD17B10
SCHEMBL6292217 0.85 ALOX15 (0.42) CYP2C9TBXA2RADRA1ASLC6A3ABCB11
SCHEMBL8342908 0.85 NR3C2 (0.41) CYP2C9TBXA2RADRA1ASLC6A3ABCB11
SCHEMBL6293708 0.85 CA1 (0.45) KDM4EMEN1KMT2AHSD17B10ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6977262-B2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2005-12-20 US disclosed
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-03-18 US disclosed
EP-1355909-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-10-29 EP disclosed
WO-2002062795-A9 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2002-10-10 WO disclosed
WO-2002062795-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof GSK3B, GSK3A, PYGB CYP2C9 1705/4885TBXA2R 3650/4885ADRA1A 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.